Boston Scientific Corporation
Board Member Yoshiaki Fujimori to Depart Boston Scientific
Summary
On February 2, 2026, Yoshiaki Fujimori, a member of Boston Scientific Corporation's Board of Directors since July 2016 and chair of the Risk, Science and Technology Committee, announced that he will not stand for re-election at the 2026 Annual Meeting. His departure is not due to any disagreement with the Company. The Board will review the size and composition of the Board and may consider adding new directors.
Profitelligence Alerts
Get alerts for BSX
Be first to know when Boston Scientific Corporation files with the SEC.
Filing Categories
Advertisement
About Boston Scientific Corporation
Boston Scientific Corporation, a leading global medical device company, is renowned for developing and supplying innovative health solutions. Its primary function is to design, manufacture, and market medical devices used in interventional medical specialties such as cardiology, peripheral interventions, cardiac rhythm management, endoscopy, urology, and neuromodulation. The company's product offerings significantly impact sectors like health care, particularly those focusing on minimally invasive treatments. Boston Scientific's products help improve the quality of patient care and reduce the need for major surgery, thus playing a crucial role in modern healthcare systems. Their devices contribute to procedures that are less invasive, more effective, and often more economic, supporting better patient outcomes and quicker recovery times. Founded in 1979 and headquartered in Marlborough, Massachusetts, Boston Scientific provides its products to healthcare providers and institutions worldwide. In the financial markets, Boston Scientific Corporation holds significant influence as a major player in the healthcare industry, contributing to advancements in medical technology and shaping the future of patient care through research and development. Its presence underscores the importance of innovation in medical devices and its role in enhancing healthcare delivery.
Official SEC Documents
Advertisement